Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. - Wikidata - wikimedia - TriplyDB

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

http://www.wikidata.org/entity/Q43873918

about

Risperidone versus other atypical antipsychotics for schizophrenia Clozapine versus other atypical antipsychotics for schizophrenia Olanzapine versus other atypical antipsychotics for schizophrenia Olanzapine for schizophrenia Risperidone versus olanzapine for schizophrenia A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy An initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.Clozapine-induced blood dyscrasias in Saudi Arab patients.Positive and Negative Syndrome Scale as a long-term outcome measurement tool in patients receiving clozapine ODT- A Pilot Study Strategies for Early Non-response to Antipsychotic Drugs in the Treatment of Acute-phase Schizophrenia Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain.Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study.Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder.Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.The therapeutic effectiveness of risperidone on negative symptoms of schizophrenia in comparison with haloperidol: a randomized clinical trial.Placebo response in antipsychotic clinical trials: a meta-analysis.Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial.Can we make smart choices between OLS and contaminated IV methods?Atypical antipsychotics for acute agitation. New intramuscular options offer advantages.Optimizing dosing in atypical neuroleptic monotherapy Cardiovascular morbidity and mortality in bipolar disorder.Cost comparisons of olanzapine and risperidone in treating schizophrenia.Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder.The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers.Olanzapine: a critical review of recent literature.Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants.Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment.Symptom domains of schizophrenia: the role of atypical antipsychotic agents.Improving patient outcomes in schizophrenia: achieving remission.

P2860

Q24234950-6388CD85-1A0E-4D56-98A8-41B63C17768A Q24236422-90C455F6-599A-4AC4-AEAE-4E86928B6E21 Q24236545-218EB049-354A-4F35-B59F-B51D7685858A Q24244031-CB1AC192-076A-409A-98A1-C7FDC09588DF Q24246232-4810C5A6-52A7-4807-A9A2-41CCA4559A43 Q24794849-9E538D8B-8E73-4103-B40E-F62F17E568DB Q28280783-4C539A16-5409-4D73-84C6-7B6629B9A1B6 Q28394341-7F9BC8FE-191D-4CBC-9C2A-AA407C8F48C7 Q30436445-E2AFC378-5B0D-425A-9AF4-7D3262E5C1BE Q30485065-EFB01E07-EA96-4B09-9E60-32843273E24D Q30491026-EFDD753C-1C8C-4291-992F-993C4AEFC24C Q33223628-7BFCB61E-75A6-4456-B0D2-BB6E35471610 Q33235110-A7CD5BC5-8B6A-4FFC-BC9B-0DC887F2AD04 Q33415861-5B9354ED-0B8D-4969-B751-9440AF6B0777 Q33462914-76837EBC-0E2F-4319-AA1A-90A1ACC2B9BC Q33618932-8269770C-3BD7-4BA6-BDB4-E8363728847A Q33660225-5A10B556-C694-4BC6-B631-E5486B6E8C57 Q34333212-817135A9-DE73-4007-AB2C-A99C1732D61C Q34335555-06906066-A71B-4F41-BDD0-08A4332ABA0F Q34338202-433D7402-C547-403F-95B3-C16485FAE308 Q34367950-A96185E4-D5E3-4B06-B9A5-1C463686708D Q34443837-E62FBDD8-1E76-485B-A2E5-907D7BC90D2A Q34590400-D097C7E9-F128-45DE-B177-C91FAB4FA7A7 Q34640811-B05F648D-DA5E-4C5E-9914-F314DE35C9F7 Q34660593-A9E2C6A5-C612-4C9F-932D-36B198F46CC8 Q34665354-2017A543-245E-45FD-AE62-67391AC67995 Q34716524-551482D3-9DF2-46CB-9524-3C2086A86882 Q34809222-277B0C46-E78C-405B-949F-E354AC54D25F Q35037851-8C297EB0-AE48-4C49-9A07-0F1283620F33 Q35236514-04CF644A-EA67-4A55-B4E1-0B2C67EA2856 Q35313130-621BA1BF-EFDE-4E7B-BE78-1983C4B431C8 Q35638077-330E158E-64D7-4E58-8C0E-F3100A67214C Q35914906-B0D567AE-9B00-47EA-9BB5-86916C53B18A Q35930948-9B2594A2-6961-4919-8AA3-72BA26A4D723 Q36034676-D43E7E4B-29FA-4499-9612-813BB05836C0 Q36273449-57B102BF-C0F7-4EBA-A875-ED10FA56C04F Q36503217-7F550092-7A28-47C6-A789-06B2FA2FA6D4 Q36580637-306E3542-34C0-4BCE-9664-C66E86FAE3F6 Q36626242-75123F55-30D5-46DC-83C2-F1D1555CFFBE Q36626254-39441717-AFE3-460A-AC41-94C210F5763C

P2860

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

http://www.wikidata.org/entity/Q43873918

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Clozapine, olanzapine, risperi ...... and schizoaffective disorder.

@en

Clozapine, olanzapine, risperi ...... and schizoaffective disorder.

@nl

type

label

Clozapine, olanzapine, risperi ...... and schizoaffective disorder.

@en

Clozapine, olanzapine, risperi ...... and schizoaffective disorder.

@nl

prefLabel

Clozapine, olanzapine, risperi ...... and schizoaffective disorder.

@en

Clozapine, olanzapine, risperi ...... and schizoaffective disorder.

@nl

P1433

Q43873918-56DD4CF0-D1F5-47BF-B76C-178467B85B27

P1476

Q43873918-C1C1F1B8-78EA-42F6-808D-12BA767D5947

P2093

Q43873918-240FD756-4DF8-4058-91E5-7E43C1B99B84

Q43873918-66D23BC7-2666-4D8F-B7AB-0B8DD6D060B0

Q43873918-82C205B2-38C2-4448-8DF9-49E7FC5830D7

Q43873918-BF23AF2E-3B22-4DB6-BFC7-620E9CC54F0D

Q43873918-BF7875B3-0EAE-4A3D-AFD2-5BC4E971221A

Q43873918-E721D61B-7F35-4131-B687-227DAA9A67AA

P304

Q43873918-77E9DA04-4A0E-43D4-BCA4-E813C7F63462

P31

Q43873918-861A9AFA-6F36-407B-8AB1-C86E5385162B

P356

Q43873918-D773B37D-66F1-42D5-9843-EDBDE496CFCF

P407

Q43873918-905F6849-F8BE-48CA-B161-0A0E9B2EB0C2

P433

Q43873918-959B3F12-664C-4BC9-B382-62C2CF3A0D0F

P478

Q43873918-2D2BC173-B37D-4F29-92DB-707347F2927A

P50

Q43873918-33ACA81E-C7FE-44B6-A773-A111589BA198

Q43873918-6EE7A7C1-BBD4-4889-9572-07A1D3EAA4CB

Q43873918-F8DAB53F-4CD6-45D0-B317-5F57BEA765F1

P577

Q43873918-991C63E3-CD8B-4F9F-8301-544AFBDCF917

P5875

Q43873918-2D770FD9-F0D1-4716-B0E5-F6D6E297D59A

P698

Q43873918-BC23AF39-130A-4920-8815-654266A84D76

P921

Q43873918-59CDBCA8-AA83-4A93-8188-0FC5EC76E1A9

Q43873918-5E2D9E80-FDD0-4EF7-B489-567F7B334377

P356

APPI.AJP.159.2.255

P1433

American Journal of Psychiatry

P1476

Clozapine, olanzapine, risperi ...... a and schizoaffective disorder

@en

P2093

Brian Sheitman

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Lindenmayer

http://www.w3.org/2001/XMLSchema#string

Joseph P McEvoy

http://www.w3.org/2001/XMLSchema#string

Miranda Chakos

http://www.w3.org/2001/XMLSchema#string

Pal Czobor

http://www.w3.org/2001/XMLSchema#string

Thomas B Cooper

http://www.w3.org/2001/XMLSchema#string

P304

255-262

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1176/APPI.AJP.159.2.255

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

159

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey Lieberman

P577

2002-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11537467

http://www.w3.org/2001/XMLSchema#string

P698

11823268

http://www.w3.org/2001/XMLSchema#string

P921